Kimball Electronics, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No.)

KIMBALL ELECTRONICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Notice of 2025 Annual Meeting and Proxy Statement

LETTER FROM OUR CEO

To Our Share Owners:

As I completed my second full year as CEO of Kimball Electronics, I once again reflected on the privilege I feel to be writing to you today. Our Company has a rich history of excellence, a genuine focus on long-term relationships, and Guiding Principles that have stood the test of time…influencing actions and behaviors as we live them each and every day. It is truly humbling to be in a position of leadership for an organization with such a distinguished pedigree.

This past year, we experienced a challenging operating environment with prolonged demand softness in the vertical markets we serve, unprecedented geopolitical uncertainty, and the loss of two major programs that were not a result of our actions but certainly resulted in significant impacts on our operations. Yet despite these headwinds, our team demonstrated remarkable resilience and perseverance, we strengthened our company culture, and we delivered record-setting results in areas where we were “controlling what we could control”:

•In fiscal year 2025, we earned our third highest annual revenue in our 60+ year history, with 75% coming from customers that we have worked with for a decade or more;

•We recorded a record number of wins for future business;

•We reached a 15-year high in our quality ratings;

•For the eleventh consecutive year, we achieved the Highest Overall Customer Ratings from CIRCUITS ASSEMBLY in the seven categories of dependability and timely delivery, manufacturing quality, responsiveness, technology, value for the price, flexibility, and overall satisfaction;

•We achieved an all-time best in cash generated from operating activities;

•We paid down our debt to its lowest level in 3 years; and

•We returned $12 million to you, our Share Owners, through share repurchases.

Unfortunately, we also had to make some difficult decisions, ones we did not take lightly as they directly impacted friends and coworkers. We completed our divestiture of the non-core Automation, Test, and Measurement business in the fiscal year, and we announced the closure of our facility in Tampa, streamlining our network, improving global capacity utilization, aligning our electronics manufacturing footprint in the U.S. with current and long-term market demand, and positioning us to better leverage our facilities in low cost regions. We are grateful to the employees in Tampa and their accomplishments since the Reptron acquisition in 2007. The team there played a vital role during the pandemic, supplying ventilators to those in need, and we appreciate their contributions as part of Kimball.

We recognize that we cannot “cut our way to greatness.” We must also focus on top line growth. Our success in fiscal year 2025 means our balance sheet is now a competitive strength with ample liquidity to weather geopolitical unpredictability, while providing dry powder for opportunistic investments in our return to profitable growth.

Kimball has always focused on high-complexity, high-reliability programs—whether it’s braking and steering systems in vehicles, motor controls for HVAC systems or diagnostic and therapeutic equipment in the medical field. Our emphasis on quality and reliability is deeply embedded in how we operate across all verticals. Internally, we reference a ‘five 9s’ reliability standard—99.999%—as a reflection of the performance and consistency we strive for. Our medical CMO aligns well with this objective and our expertise in highly-regulated, highly-engineered, complex manufacturing environments. The recent announcement by our largest medical customer that they were making Kimball the sole supplier on their respiratory care final assembly and HLA business is a great example of our growth potential.

In the medical CMO space, we see opportunities for higher EBITDA margins. Our strategy is to pursue growth with blue chip customers who have long product life cycles and a high degree of visibility. Not only will we add capabilities, we will continue building our scalable platform that creates opportunities for vertical integration, positions us to take on more of the complex programs that align with our strengths, and supports the work we already do well, like drug delivery, one of our key areas of focus.

Our new 300,000-square-foot medical CMO facility in Indianapolis is an important milestone in this strategy. It gives us the space we need to expand our production capabilities in cold chain management, complete device assembly, and precision-molded plastics. Our current manufacturing expertise includes medical disposables, single-use surgical instruments, and selected drug delivery devices, such as auto-injectors. We’re expanding this expertise to areas such as cardiology, orthopedics, minimally invasive surgery, and surgical instruments & packaging. The medical market presents us with a compelling opportunity to diversify our revenue and leverage our core strengths as a trusted partner in a complex and highly-regulated industry. With this facility, we are well-positioned to meet current and future customer needs while staying committed to exploring inorganic options to augment this space where it makes strategic sense.

We expect fiscal year 2026 to be another step forward in this journey and anticipate positive topline growth in fiscal year 2027. Throughout, we will stay true to our Guiding Principles and continue to:

•Be collaborative and team-oriented,

•Set high aspirations with attainable targets that require stretching,

•Communicate openly and proactively, and

•Remain accountable to each other, to our Company, to our customers, and to you, our Share Owners.

I’m excited for Kimball’s future and thank you for your support.

NOTICE OF ANNUAL MEETING OF SHARE OWNERS

KIMBALL ELECTRONICS, INC.

1205 Kimball Blvd.

Jasper, Indiana 47546

(812) 634-4000

Dear Fellow Share Owners of Kimball Electronics, Inc.:

We cordially invite you to attend the annual meeting of the Share Owners (the “Annual Meeting”) of KIMBALL ELECTRONICS, INC., an Indiana corporation (the “Company”), which will be held at the Company’s facility at 1220 South Post Road, Indianapolis, Indiana, on Friday, November 14, 2025, at 10:00 A.M., Eastern Standard Time (EST). At the Annual Meeting, you will have the opportunity to vote on three important proposals:

and to consider and transact such other business as may properly come before the meeting or any adjournments thereof. Only Share Owners of record at the close of business on September 15, 2025 are entitled to notice of and to vote at the Annual Meeting.

YOUR VOTE IS VERY IMPORTANT! We hope you will attend the Annual Meeting in person. However, regardless of whether you plan to attend the meeting, it is important that your shares be represented and voted at the meeting. We encourage you to promptly vote and submit your proxy via the Internet, by toll-free telephone, or if you receive this proxy by mail, by signing, dating, and returning the enclosed proxy card in the envelope provided. If you received more than one proxy card, that is an indication that your shares are registered in more than one account. Please complete and return a proxy for each proxy card you receive. If you attend the Annual Meeting, you can vote in person even if you previously submitted your proxy.

Thank you for your continued investment in Kimball Electronics. We look forward to seeing all of you on November 14.

By Order of the Board of Directors

Douglas A. Hass

Chief Legal & Administrative Officer, Secretary